litlas
Log inCreate account

A. John Iafrate

Active 1997–2026

Also published as
A.John Iafrate
229
Papers
75,737
Citations
127
h-index
224
i10-index

Citations

Citations per year for A. John Iafrate1945: 1 citations1976: 2 citations1985: 2 citations1987: 1 citations1990: 1 citations1993: 1 citations1994: 2 citations1995: 1 citations1997: 3 citations1998: 19 citations1999: 20 citations2000: 30 citations2001: 27 citations2002: 18 citations2003: 12 citations2004: 15 citations2005: 64 citations2006: 85 citations2007: 111 citations2008: 211 citations2009: 294 citations2010: 408 citations2011: 687 citations2012: 969 citations2013: 1,058 citations2014: 966 citations2015: 1,162 citations2016: 1,111 citations2017: 1,232 citations2018: 1,199 citations2019: 2,927 citations2020: 3,182 citations2021: 3,221 citations2022: 2,730 citations2023: 1,606 citations2024: 2,160 citations2025: 1,019 citations2026: 27 citations1946–1975: no citations, so these years are not shown1977–1984: no citations, so these years are not shown1986: no citations, so this year is not shown1988–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 9,269 citing papers, 29.9% of this breakdownChina: 3,364 citing papers, 10.9% of this breakdownUnited Kingdom: 1,790 citing papers, 5.8% of this breakdownGermany: 1,617 citing papers, 5.2% of this breakdownItaly: 1,517 citing papers, 4.9% of this breakdownJapan: 1,178 citing papers, 3.8% of this breakdownFrance: 1,112 citing papers, 3.6% of this breakdownCanada: 1,010 citing papers, 3.3% of this breakdownSpain: 855 citing papers, 2.8% of this breakdownNetherlands: 768 citing papers, 2.5% of this breakdownSouth Korea: 725 citing papers, 2.3% of this breakdownSwitzerland: 719 citing papers, 2.3% of this breakdown
0%29.9%Other 22.7%

Institutions

Fields

  • Medicine56.2%
  • Biochemistry, Genetics and Molecular Biology36.6%
  • Immunology and Microbiology2%
  • Engineering1.2%
  • Computer Science0.9%
  • Agricultural and Biological Sciences0.7%
  • Other2.4%

Topics

  • Lung Cancer Treatments and Mutations7.6%
  • Cancer Genomics and Diagnostics6.2%
  • Lung Cancer Research Studies3.3%
  • CRISPR and Genetic Engineering2.6%
  • Cancer Cells and Metastasis2.5%
  • Glioma Diagnosis and Treatment2.5%
  • Other75.3%

Coauthors

All papers

Open in search
  1. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

    Authors: Shengdar Q. Tsai, Zongli Zheng, Nathalie T. Nguyen, Matthew Liebers, Ved V. Topkar, Vishal Thapar, Nicolas Wyvekens, Cyd Khayter, A. John Iafrate, Long P. Le, Martin J. Aryee, J. Keith Joung - Nature Biotechnology 2014 cited by 2,307

  2. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma

    Authors: Itay Tirosh, Andrew S. Venteicher, Christine Hebert, Leah E. Escalante, Anoop P. Patel, Keren Yizhak, Jonathan Fisher, Christopher Rodman, Christopher Mount, Mariella G. Filbin, Cyril Neftel, Niyati Desai, Jackson Nyman, Benjamin Izar, Christina C. Luo, Joshua M. Francis, Aanand A. Patel, Maristela L. Onozato, Nicolò Riggi, Kenneth J. Livak, Dave Gennert, Rahul Satija, Brian V. Nahed, William T. Curry, Robert L. Martuza, Ravindra Mylvaganam, A. John Iafrate, Matthew P. Frosch, Todd R. Golub, Miguel N. Rivera, Gad Getz, Orit Rozenblatt–Rosen, Daniel P. Cahill, Michelle Monje, B Bernstein, David N. Louis, Aviv Regev, Mario L. Suvà - Nature 2016 cited by 1,372

  3. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

    Authors: Andrew S. Venteicher, Itay Tirosh, Christine Hebert, Keren Yizhak, Cyril Neftel, Mariella G. Filbin, Volker Hovestadt, Leah E. Escalante, McKenzie Shaw, Christopher Rodman, Shawn Gillespie, Danielle Dionne, Christina C. Luo, Hiranmayi Ravichandran, Ravindra Mylvaganam, Christopher Mount, Maristela L. Onozato, Brian V. Nahed, Hiroaki Wakimoto, William T. Curry, A. John Iafrate, Miguel N. Rivera, Matthew P. Frosch, Todd R. Golub, Priscilla K. Brastianos, Gad Getz, Anoop P. Patel, Michelle Monje, Daniel P. Cahill, Orit Rozenblatt–Rosen, David N. Louis, B Bernstein, Aviv Regev, Mario L. Suvà - Science 2017 cited by 1,090

  4. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Authors: Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata, Subba R. Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer S. Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman - Science Translational Medicine 2011 cited by 3,556

  5. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

    Authors: Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, María Gomez‐Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Yosef E. Maruvka, Fei Ji, Hyo-Eun Carrie Bhang, Viveksagar Krishnamurthy Radhakrishna, Giulia Siravegna, Haichuan Hu, Sana Raoof, Elizabeth L. Lockerman, Anuj Kalsy, Dana Lee, Celina L Keating, David A. Ruddy, Leah J. Damon, Adam Crystal, Carlotta Costa, Zofia Piotrowska, Alberto Bardelli, A. John Iafrate, Ruslan I. Sadreyev, Frank Stegmeier, Gad Getz, Lecia V. Sequist, Anthony C. Faber, Jeffrey A. Engelman - Nature Medicine 2016 cited by 999

  6. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Authors: Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2014 cited by 1,993

  7. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Authors: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 cited by 1,744

  8. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

    Authors: Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, Lipika Goyal, Chaya Levovitz, Giulia Siravegna, Dimitri Livitz, Kahn Rhrissorrakrai, Elizabeth E. Martin, Emily E. Van Seventer, Megan Hanna, Kara Slowik, Filippo Utro, Christopher J. Pinto, Alicia Wong, Brian P. Danysh, Ferran Fece de la Cruz, Isobel J. Fetter, Brandon Nadres, Heather A. Shahzade, Jill N. Allen, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Bruce J. Giantonio, Janet E. Murphy, Ryan David Nipp, Eric Roeland, David P. Ryan, Colin D. Weekes, Eunice L. Kwak, Jason E. Faris, Jennifer Y. Wo, François Aguet, Ipsita Dey‐Guha, Mehlika Hazar-Rethinam, Dora Dias‐Santagata, David T. Ting, Andrew X. Zhu, Theodore S. Hong, Todd R. Golub, A. John Iafrate, Viktor A. Adalsteinsson, Alberto Bardelli, Laxmi Parida, Dejan Juric, Gad Getz, Ryan B. Corcoran - Nature Medicine 2019 cited by 522

  9. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer

    Authors: Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo‐Jack, Shirish M. Gadgeel, Katherine R. Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth L. Lockerman, Tiffany G. Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba R. Digumarthy, Colleen L. Channick, Colleen Keyes, Gad Getz, Dora Dias‐Santagata, Rebecca S. Heist, Jochen K. Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw - Cancer Discovery 2016 cited by 1,144

  10. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

    Authors: Wilfredo F. García-Beltrán, Kerri St. Denis, Angelique Hoelzemer, Evan C. Lam, Adam D. Nitido, Maegan L. Sheehan, Cristhian Berrios, Onosereme Ofoman, Christina C. Chang, Blake M. Hauser, Jared Feldman, Alex Roederer, David J. Gregory, Mark C. Poznansky, Aaron G. Schmidt, A. John Iafrate, Vivek Naranbhai, Alejandro B. Balazs - Cell 2022 cited by 1,098

  11. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

    Authors: Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura E. Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu - Cancer Discovery 2016 cited by 545

  12. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

    Authors: A. Shaw, G.J. Riely, Yung‐Jue Bang, Donghyeon Kim, D.R. Camidge, Benjamin Solomon, Marileila Varella‐Garcia, A. John Iafrate, Geoffrey I. Shapiro, Tiziana Usari, Stewart C. Wang, Keith D. Wilner, Jeffrey W. Clark, S.‐H.I. Ou - Annals of Oncology 2019 cited by 577

  13. Anchored multiplex PCR for targeted next-generation sequencing

    Authors: Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D. Lynch, Juxiang Chen, Hayley Robinson, Hyo Sup Shim, Juliann Chmielecki, William Pao, Jeffrey A. Engelman, A. John Iafrate, Long P. Le - Nature Medicine 2014 cited by 917

  14. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Authors: Lipika Goyal, Lei Shi, Leah Y. Liu, Ferran Fece de la Cruz, Jochen K. Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W.S. Ng, Phuong Vu, Krushna C. Patra, Supriya K. Saha, Raul N. Uppot, Ron Arellano, Stephanie Reyes, Takeshi Sagara, Sachie Otsuki, Brandon Nadres, Heather A. Shahzade, Ipsita Dey‐Guha, Isobel J. Fetter, Islam Baiev, Emily E. Van Seventer, Janet E. Murphy, Cristina R. Ferrone, Kenneth K. Tanabe, Vikram Deshpande, James J. Harding, Rona Yaeger, Robin Kate Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy - Cancer Discovery 2019 cited by 371

  15. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Authors: Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson, Subba R. Digumarthy, Daniel B. Costa, Rebecca S. Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott, Jeffrey Settleman, Susumu Kobayashi, Eugene J. Mark, Scott J. Rodig, Lucian R. Chirieac, Eunice L. Kwak, Thomas J. Lynch, A. John Iafrate - Journal of Clinical Oncology 2009 cited by 1,882

  16. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Authors: Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina T. Siwak-Tapp, Adriana González, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino–Kenudson, William Pao, A. John Iafrate - Journal of Clinical Oncology 2012 cited by 1,557

  17. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

    Authors: Matthew J. Niederst, Lecia V. Sequist, John T. Poirier, Craig H. Mermel, Elizabeth L. Lockerman, Angel R. Garcia, Ryohei Katayama, Carlotta Costa, Kenneth N. Ross, Teresa Morán, Emily Howe, Linnea Fulton, Hillary E. Mulvey, Lindsay A. Bernardo, Farhiya Mohamoud, Norikatsu Miyoshi, Paul A. VanderLaan, Daniel B. Costa, Pasi A. Jänne, Darrell R. Borger, Sridhar Ramaswamy, Toshi Shioda, A. John Iafrate, Gad Getz, Charles M. Rudin, Mari Mino–Kenudson, Jeffrey A. Engelman - Nature Communications 2015 cited by 633

  18. The NCI-MATCH trial: lessons for precision oncology

    Authors: Peter J. O’Dwyer, Robert J. Gray, Keith T. Flaherty, Alice P. Chen, Shuli Li, Victoria Wang, Lisa M. McShane, David R. Patton, James V. Tricoli, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Edith P. Mitchell, Naoko Takebe, David Sims, Brent Coffey, Tony Fu, Mark J. Routbort, Larry Rubinstein, Richard F. Little, Carlos L. Arteaga, Donna M. Marinucci, Stanley R. Hamilton, Barbara A. Conley, Lyndsay N. Harris, James H. Doroshow - Nature Medicine 2023 cited by 183

  19. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

    Authors: Kensuke Tateishi, Hiroaki Wakimoto, A. John Iafrate, Shota Tanaka, Franziska Loebel, Nina Lelic, Dmitri Wiederschain, Olivier Bedel, Gejing Deng, Bailin Zhang, Timothy He, Xu Shi, Robert E. Gerszten, Yiyun Zhang, Jing-Ruey Joanna Yeh, William T. Curry, Dan Zhao, Sudhandra Sundaram, Fares Nigim, Mara V.A. Koerner, Quan Van Ho, David E. Fisher, Elisabeth Roider, Lajos V. Kemény, Yardena Samuels, Keith T. Flaherty, Tracy T. Batchelor, Andrew S. Chi, Daniel P. Cahill - Cancer Cell 2015 cited by 445

  20. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Authors: Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2010 cited by 4,504

  21. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

    Authors: Rosaria Condorelli, Laura M. Spring, Joyce O’Shaughnessy, Ludovic Lacroix, Caroline Bailleux, Véronique Scott, Jon S. Dubois, Rebecca J. Nagy, Richard B. Lanman, A. John Iafrate, Fabrice André, Aditya Bardia - Annals of Oncology 2017 cited by 404

  22. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

    Authors: Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo‐Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino–Kenudson, Jeffrey A. Engelman, Ted W. Johnson, Aaron N. Hata, Alice T. Shaw - Cancer Discovery 2018 cited by 306

  23. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

    Authors: Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Shuli Li, Lisa M. McShane, David R. Patton, Stanley R. Hamilton, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Edith P. Mitchell, Lyndsay N. Harris, Naoko Takebe, David Sims, Brent Coffey, Tony Fu, Mark J. Routbort, James A. Zwiebel, Larry Rubinstein, Richard F. Little, Carlos L. Arteaga, Robert L. Comis, Jeffrey S. Abrams, Peter J. O’Dwyer, Barbara A. Conley, for the NCI-MATCH team - Journal of Clinical Oncology 2020 cited by 295

  24. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

    Authors: Min Yu, Aditya Bardia, Nicola Aceto, Francesca Bersani, Marissa W. Madden, Maria Donaldson Collier, Rushil Desai, Huili Zhu, Valentine Comaills, Zongli Zheng, Ben S. Wittner, Petar Stojanov, Elena F. Brachtel, Dennis C. Sgroi, Ravi Kapur, Toshi Shioda, David T. Ting, Sridhar Ramaswamy, Gad Getz, A. John Iafrate, Cyril H. Benes, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber - Science 2014 cited by 913